Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event

Rhea-AI Summary

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announces participation of RA Session II, President and CEO, in two panels at the LifeSci Partners 11th Annual Corporate Access Event on January 6, 2022. The first panel, titled Gene Therapy: Reaching its Full Potential, occurs at 11:00 AM ET, while the second, Patient Advocacy: Honing the Skill for Crossover Communications, takes place at 2:00 PM ET. Viewers can access the webcasts through the company's website, which also offers archived versions for 60 days.

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that RA Session II, President, Founder and CEO of Taysha, will participate in two panel discussions during the LifeSci Partners 11^th Annual Corporate Access Event.

Details for the panel discussions are below:

Title:	Gene Therapy: Reaching its Full Potential
Date:	Thursday, January 6, 2022
Time:	11:00 AM ET
Webcast:	https://wsw.com/webcast/lifesci3/panel8/2389200

Title:	Patient Advocacy: Honing the Skill for Crossover Communications between Patients and Stakeholders
Date:	Thursday, January 6, 2022
Time:	2:00 PM ET
Webcast:	https://wsw.com/webcast/lifesci3/panel10/2456850

A webcast of the panels will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005109/en/

Company Contact:

Kimberly Lee, D.O.

SVP, Corporate Communications and Investor Relations

Taysha Gene Therapies

klee@tayshagtx.com

Media Contact:

Carolyn Hawley

Canale Communications

carolyn.hawley@canalecomm.com

Source: Taysha Gene Therapies, Inc.

FAQ

What is the date of Taysha Gene Therapies' participation in the LifeSci Partners event?

Taysha Gene Therapies will participate in the LifeSci Partners event on January 6, 2022.

Who is presenting at the LifeSci Partners 11th Annual Corporate Access Event for TSHA?

RA Session II, the President and CEO of Taysha Gene Therapies, will present at the event.

What topics will Taysha Gene Therapies cover during the panels?

The topics include Gene Therapy: Reaching its Full Potential and Patient Advocacy: Honing the Skill for Crossover Communications.

What are the webcast times for the TSHA panels on January 6, 2022?

The first panel starts at 11:00 AM ET and the second at 2:00 PM ET.

Where can I find the webcasts for Taysha Gene Therapies' panels?

The webcasts can be found in the 'Events & Media' section of Taysha's corporate website.